<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306224</url>
  </required_header>
  <id_info>
    <org_study_id>IMC-002-101</org_study_id>
    <nct_id>NCT04306224</nct_id>
  </id_info>
  <brief_title>A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas</brief_title>
  <official_title>A First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmuneOncia Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmuneOncia Therapeutics Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first-in-human, Phase I, open-label, multiple-ascending dose study to investigate&#xD;
      the safety, tolerability, PK, PharmDyn, and clinical activity of IMC-002 in subjects with&#xD;
      metastatic or locally advanced solid tumors and relapsed or refractory lymphomas.&#xD;
&#xD;
      Male or female subjects 18 years and older with metastatic or locally advanced solid tumors&#xD;
      and relapsed or refractory lymphomas will be included in the study if they meet all the&#xD;
      inclusion criteria and none of the exclusion criteria.&#xD;
&#xD;
      The study will consist of 2 parts:&#xD;
&#xD;
      Part 1: Dose Escalation Part 2: Expansion Cohorts&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: Dose Escalation&#xD;
&#xD;
      Part 2: Expansion Cohort The study may be amended in the future to include expansion cohorts&#xD;
      in selected tumor types to further evaluate extended safety of IMC-002 at recommended Phase 2&#xD;
      dose in that tumor type. Sample size in the Dose Expansion part will be determined when the&#xD;
      study is amended to include the expansion cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose escalation will consist of two distinct sub-parts (1A and 1B).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose-limiting toxicities (DLT)</measure>
    <time_frame>For 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>IMC-002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation will follow the traditional 3+3 design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-002</intervention_name>
    <description>IMC-002 blocks the interaction between CD47 and SIRPα.</description>
    <arm_group_label>IMC-002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subjects are eligible to be included in the study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
          1. Signed informed consent form (ICF)&#xD;
&#xD;
          2. Adult (18 years or older)&#xD;
&#xD;
          3. Histologically or cytologically proven metastatic or locally advanced solid tumors and&#xD;
             relapsed or refractory lymphomas, for which no standard therapy known to prolong&#xD;
             survival exists or have relapsed/refractory/PD following the last line of treatment&#xD;
&#xD;
          4. Solid tumors must be measurable with at least 1 unidimensional measurable lesion by&#xD;
             Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Lymphomas must&#xD;
             have at least 1 measurable lesion according to the Lugano criteria with the Lymphoma&#xD;
             Response to Immunomodulatory Therapy Criteria (LYRIC) modification&#xD;
&#xD;
          5. Availability of tumor archival material or fresh biopsies for measurement of CD47&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening&#xD;
             and an estimated life expectancy of at least 3 months&#xD;
&#xD;
          7. Adequate hematologic function, hepatic function, and renal function&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          1. Treatment with nonpermitted drugs (within 28 days before Day 1).&#xD;
&#xD;
          2. Prior treatment with a CD47 or SIRPα targeting agent&#xD;
&#xD;
          3. Concurrent anticancer treatments within 28 days before Day 1/first study treatment&#xD;
             administration&#xD;
&#xD;
          4. Major surgery or significant traumatic injury within 6 weeks prior to Screening or&#xD;
             planned major surgery during the study period&#xD;
&#xD;
          5. Previous malignant disease other than the target malignancy for this study, except&#xD;
             adequately treated Stage I or II cancers from which the subject is currently in&#xD;
             complete remission per the Investigator's clinical judgment&#xD;
&#xD;
          6. Primary central nervous system (CNS) disease or leptomeningeal disease; known CNS&#xD;
             metastases unless treated&#xD;
&#xD;
          7. Comorbidities/medical history of any significant diseases that in the judgment of the&#xD;
             Investigator would make the subject inappropriate for this study&#xD;
&#xD;
          8. Active infection requiring systemic therapy within 14 days before Day 1&#xD;
&#xD;
          9. Persisting toxicities Grade &gt; 1 NCI-CTCAE Version 5.0 related to prior anticancer&#xD;
             treatment&#xD;
&#xD;
         10. Pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Hye Lee</last_name>
    <role>Study Director</role>
    <affiliation>ImmuneOncia Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Hye Lee</last_name>
    <phone>+82 31 306 8199</phone>
    <email>jhlee@immuneoncia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EunJeong Seo</last_name>
    <phone>+82 31 306 8195</phone>
    <email>EJSeo@immuneoncia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine - Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassy Benedict</last_name>
      <phone>314-273-3127</phone>
      <email>cassy.benedict@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Haeseong Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey McQuinn, MPH, CCRP</last_name>
      <phone>713-792-5578</phone>
      <email>lmcquinn@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Aung Naing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Betancourt, MS, M.Jur.</last_name>
      <phone>210-580-9513</phone>
      <email>abetancourt@nextoncology.com</email>
    </contact>
    <investigator>
      <last_name>Raghad M. Abdul Karim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heekyoung Koo</last_name>
      <phone>+82 2 2072 1672</phone>
      <email>kooheekyoung@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bhumsuk KIM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMC-002</keyword>
  <keyword>Phase I</keyword>
  <keyword>CD47</keyword>
  <keyword>SIRPα</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

